Literature DB >> 27480776

The Impacts of miRNAs in Glioblastoma Progression.

Rasime Kalkan1, Emine İkbal Atli2.   

Abstract

miRNAs are short noncoding RNA sequences that cause translational repression or mRNA degradation. A growing number of studies have sought new biomarkers in GBM that will be important in disease progression and prognosis and as potential therapeutic targets. miRNA-profiling studies in glioblastoma patients have found that aberrant miRNA expression can be used as a target to develop new biomarkers for disease detection and for determining prognosis or therapeutic response. In evaluating the tumor or its therapeutic response, genetic abnormalities such as mutations, epigenetic abnormalities, and aberrant miRNA expressions can be useful markers. This review summarizes the known miRNAs according their therapeutic importance and their use as disease progression biomarkers.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27480776     DOI: 10.1615/CritRevEukaryotGeneExpr.2016015964

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  4 in total

1.  MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.

Authors:  Tian Tian; Ma Mingyi; Xia Qiu; Yang Qiu
Journal:  Oncotarget       Date:  2016-11-29

2.  Plasma microRNA-720 may predict prognosis and diagnosis in glioma patients.

Authors:  Peng Chen; Guangying Zhang; Qin Zhou; Zhanzhan Li
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

3.  Effects of miR-373 Inhibition on Glioblastoma Growth by Reducing Limk1 In Vitro.

Authors:  Tao Peng; Tiejun Wang; Guohui Liu; Lixiang Zhou
Journal:  J Immunol Res       Date:  2020-09-28       Impact factor: 4.818

4.  The Status of EGFR Modulates the Effect of miRNA-200c on ZEB1 Expression and Cell Migration in Glioblastoma Cells.

Authors:  Lisandra Muñoz-Hidalgo; Teresa San-Miguel; Javier Megías; Eva Serna; Silvia Calabuig-Fariñas; Daniel Monleón; Rosario Gil-Benso; Miguel Cerdá-Nicolás; Concha López-Ginés
Journal:  Int J Mol Sci       Date:  2020-12-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.